CompletedNCT06280235
BI 1569912 dose study for people taking depression medication
About this title
Read the official source — NCT06280235Medication studyAges 18–65Multiple countries
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Tucson and 51 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: March 27, 2024
- Recruitment status
- Completed
- Enrollment listed in the registry
- 243
- Sponsor
- Boehringer Ingelheim
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States, Belgium, Bulgaria, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06280235
- Official title
Show the full official title
A Phase II, 6-week, Multicenter, Randomized, Double Blind (Patient and Investigator) or Masked, Placebo Controlled, Dose-finding Trial to Evaluate the Efficacy, Tolerability, and Safety of Different Doses of Oral BI 1569912 as Adjunctive Therapy in MD
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Tucson, United States · Oceanside, United States · Orange, United States
42 more locations
- Panorama City, United States
- Cromwell, United States
- Hialeah, United States
- Miami, United States
- Decatur, United States
- Chicago, United States
- Methuen, United States
- Roslindale, United States
- Watertown, United States
- Marlton, United States
- Cedarhurst, United States
- Dayton, United States
- North Canton, United States
- Oklahoma City, United States
- Bellaire, United States
- Wichita Falls, United States
- Bellevue, United States
- Alken, Belgium
- Duffel, Belgium
- Cherven Bryag, Bulgaria
- Rousse, Bulgaria
- Sofia, Bulgaria
- Varna, Bulgaria
- Baoding, China
- Beijing, China
- Changsha, China
- Shanghai, China
- Shenzhen, China
- Shijiazhuang, China
- Tianjin, China
- Pilsen, Czechia
- Prague, Czechia
- Berlin, Germany
- Schwerin, Germany
- Anan-shi, Japan
- Fukuoka, Japan
- Fukuoka, Fukuoka, Japan
- Karatsu-shi, Japan
- Kurume-shi, Japan
- Mitaka-shi, Japan
- Shibuya-ku, Japan
- Czechia
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Boehringer Ingelheim.
Did this study involve medication?
Yes. The study involved medication, including BI 1569912 and Placebo.
Who was this study for?
Listed age limits: 18 years to 65 years.
